Vietnamese Health Care Providers' Preferences Regarding Recommendation of HPV Vaccines

  • Asiedu, Gladys B (Department of Health Sciences Research, Division of Health Care Policy and Research, Mayo Clinic) ;
  • Breitkopf, Carmen Radecki (Department of Health Sciences Research, Division of Health Care Policy and Research, Mayo Clinic) ;
  • Kremers, Walter K (Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic) ;
  • Ngo, Quang V (Da Nang Center for Reproductive Health) ;
  • Nguyen, Nguyen V (Department of Radiology, Jackson Memorial Hospital/University of Miami) ;
  • Barenberg, Benjamin J (Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center) ;
  • Tran, Vinh D (Da Nang Hospital for Women and Children) ;
  • Dinh, Tri A (Department of Gynecologic Oncology & Gynecologic Surgery, Mayo Clinic)
  • Published : 2015.07.13


Physician recommendation is an important predictor of HPV vaccine acceptance; however, physician willingness and preferences regarding HPV vaccination may be influenced by factors including patient age, vaccine type, and cost. A cross-sectional survey was administered to a convenience sample of health care providers in Da Nang, Vietnam, to evaluate awareness, perceptions about HPV and HPV vaccines, and willingness to vaccinate a female patient. Willingness to vaccinate was evaluated using a full-factorial presentation of scenarios featuring the following factors: vaccine cost (free vs 1,000,000 VND), patient age (12, 16, or 22 years), and HPV vaccine type (bivalent vs quadrivalent). Responses from 244 providers were analyzed; providers had a mean age of $34{\pm}11.9$ years; a majority were female, married, and had children of their own. Thirty-six percent specialized in obstetrics/gynecology and 24% were providers in family medicine. Of the three factors considered in conjoint analysis, vaccine cost was the most important factor in willingness to vaccinate, followed by patient age, and vaccine type. The most favorable scenario for vaccinating a female patient was when the vaccine was free, the patient was 22 years of age, and the HPV4 vaccine was described. In multivariable analysis, older age, being a physician, being married, and having children were all associated with increased willingness to recommend HPV vaccination (p<0.05). Provider willingness is an important aspect of successful HPV vaccination programs; identifying preferences and biases in recommendation patterns will highlight potential areas for education and intervention.


Cervical cancer prevention;conjoint analysis;human papillomavirus vaccine;provider preferences


  1. Breitkopf CR, Pearson HC, Dinh TA, et al (2009). Human papillomavirus vaccine decision-making in Da Nang, Vietnam: perceived spousal and adolescent-parent concordance. Vaccine, 27, 2367-71.
  2. Bruni L, Barrionuevo-Rosas L, Albero G, et al (2014). ICO information centre on HPV and cancer (HPV information centre). human papillomavirus and related diseases in Viet Nam. Summary Report 2014-12-18.
  3. Caskey R, Lindau ST, Alexander GC (2009). Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health, 45, 453-62.
  4. Centers for Disease Control and Prevention (2013a). HPV vaccine information for clinicians - fact sheet.
  5. Centers for Disease Control and Prevention (2013b). HPV Vaccines.
  6. Centers for Disease Control and Prevention (2013c). National and state vaccination coverage among adolescents aged 13-17 years--United States, 2012. MMWR Morb Mortal Wkly Rep, 62, 685-93.
  7. Cover JK, Nghi NQ, LaMontagne DS, et al (2012). Acceptance patterns and decision-making for human papillomavirus vaccination among parents in Vietnam: an in-depth qualitative study post-vaccination. BMC Public Health, 12, 629.
  8. Daley MF, Liddon N, Crane LA, et al (2006). A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics, 118, 2280-9.
  9. Dinh TA, Rosenthal SL, Doan ED, et al (2007). Attitudes of mothers in Da Nang, Vietnam toward a human papillomavirus vaccine. J Adolesc Health, 40, 559-63.
  10. Do H, Seng P, Talbot J, et al (2009). HPV vaccine knowledge and beliefs among Cambodian American parents and community leaders. Asian Pac J Cancer Prev, 10, 339-44.
  11. Dunne EF, Unger ER, Sternberg M, et al (2007). Prevalence of HPV infection among females in the United States. JAMA, 297, 813-9.
  12. Gargano LM, Herbert NL, Painter JE, et al (2013). Impact of a physician recommendation and parental immunization attitudes on receipt or intention to receive adolescent vaccines. Hum Vaccin Immunother, 9, 2627-33.
  13. Harper DM, Franco EL, Wheeler C, et al (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet, 364, 1757-65.
  14. Harper DM, Franco EL, Wheeler CM, et al (2006). Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet, 367, 1247-55.
  15. Hoang HT, Ishizaki A, Nguyen CH, et al (2013). Infection with high-risk HPV types among female sex workers in northern Vietnam. J Med Virol, 85, 288-94.
  16. Hofstetter AM, Stockwell MS, Al-Husayni N, et al (2014). HPV vaccination: are we initiating too late? Vaccine, 32, 1939-45.
  17. International Agency for Research on Cancer (IARC). GLOBOCAN 2012: Cervical cancer estimated incidence, mortality and prevalence worldwide in 2012.
  18. Kahn JA, Rosenthal SL, Tissot AM, et al (2007). Factors influencing pediatricians' intention to recommend human papillomavirus vaccines. Ambul Pediatr, 7, 367-73.
  19. Kester LM, Zimet GD, Fortenberry JD, et al (2013). A national study of HPV vaccination of adolescent girls: rates, predictors, and reasons for non-vaccination. Matern Child Health J, 17, 879-85.
  20. Kim JJ, Kobus KE, Diaz M, et al (2008). Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine, 26, 4015-24.
  21. LaMontagne DS, Barge S, Le NT, et al (2011). Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ, 89, 821-30.
  22. Lamontagne DS, Thiem VD, Huong VM, et al (2013). Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis, 208, 1325-34.
  23. Long LD, Population Council (Vietnam), United Nations Population Fund (2000). The Doi Moi generation: coming of age in Vietnam today. Hanoi, Vietnam: Population Council.
  24. Miyashita M, Agdamag DM, Sasagawa T, et al (2009). High-risk HPV types in lesions of the uterine cervix of female commercial sex workers in the Philippines. J Med Virol, 81, 545-51.
  25. Molano M, Van den Brule A, Plummer M, et al (2003). Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol, 158, 486-94.
  26. Nghi NQ, Lamontagne DS, Bingham A, et al (2010). Human papillomavirus vaccine introduction in Vietnam: formative research findings. Sex Health, 7, 262-70.
  27. PATH and National Institute of Hygiene and Epidemiology (NIHE) (2009). Shaping a strategy to introduce HPV vaccines in Vietnam: formative research results from the HPV vaccines: evidence for impact project.
  28. Paul P, LaMontagne DS, Le NT (2012). Knowledge of cervical cancer and HPV vaccine post-vaccination among mothers and daughters in Vietnam. Asian Pac J Cancer Prev, 13, 2587-92.
  29. Perkins RB, Anderson BL, Gorin SS, et al (2013). Challenges in cervical cancer prevention: a survey of U.S. obstetrician-gynecologists. Am J Prev Med, 45, 175-81.
  30. Poulos C, Yang JC, Levin C, et al (2011). Mothers' preferences and willingness to pay for HPV vaccines in Vinh Long Province, Vietnam. Soc Sci Med, 73, 226-34.
  31. Romanowski B, de Borba PC, Naud PS, et al (2009). Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet, 374, 1975-85.
  32. Rosenthal SL, Weiss TW, Zimet GD, et al (2011). Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation. Vaccine, 29, 890-5.
  33. Stockwell MS, Rosenthal SL, Sturm LA, et al (2011). The effects of vaccine characteristics on adult women's attitudes about vaccination: a conjoint analysis study. Vaccine, 29, 4507-11.
  34. Tsunematsu M, Kawasaki H, Masuoka Y, et al (2013). Factors affecting breast cancer screening behavior in Japan-assessment using the health belief model and conjoint analysis. Asian Pac J Cancer Prev, 14, 6041-8.
  35. Vadaparampil ST, Kahn JA, Salmon D, et al (2011). Missed clinical opportunities: provider recommendations for HPV vaccination for 11-12 year old girls are limited. Vaccine, 29, 8634-41.
  36. Villa LL, Costa RL, Petta CA, et al (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 6, 271-8.
  37. Vu LT, Bui D, Le HT (2013). Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign. BMC Cancer, 13, 53.
  38. Vu LT, Le HT (2011). Cervical human papilloma virus infection among the general female population in Vietnam: a situation analysis. Asian Pac J Cancer Prev, 12, 561-6.
  39. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.<12::AID-PATH431>3.0.CO;2-F
  40. World Health Organization (WHO) (2014). Evidence based recommendations on human papilloma virus (HPV) vaccines schedules. Background paper for SAGE discussions, March 11, 2014.
  41. Ylitalo KR, Lee H, Mehta NK (2013). Health care provider recommendation, human papillomavirus vaccination, and race/ethnicity in the US national immunization survey. Am J Public Health, 103, 164-9.

Cited by

  1. Acceptability of two- versus three-dose human papillomavirus vaccination schedule among providers and mothers of adolescent girls: a mixed-methods study in five countries pp.1573-7225, 2018,
  2. Prevalence of human papillomavirus by geographical regions, sexual orientation and HIV status in China: a systematic review and meta-analysis vol.94, pp.6, 2018,